Radiation therapy for localized low-grade non-Hodgkin's lymphomas

Hematological Oncology

Volumn 23, Issue 1, 2005, Pages 10-17

  Tsang, Richard W ^a   Gospodarowicz, Mary K ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Follicular lymphoma; Low grade lymphoma; MALT lymphoma; Marginal zone lymphoma; Radiation therapy; Treatment

Indexed keywords

CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE ASSOCIATION; FOLLICULAR LYMPHOMA; HELICOBACTER PYLORI; HUMAN; MORBIDITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; SURVIVAL;

HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; RECURRENCE; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 27744608866     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/hon.743     Document Type: Review

References (79)

1. Jaffe ES, Harris NL, Stein H, et al. (eds). Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001.
2. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780-2795.
3. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-1265.
4. Ha CS, Cabanillas F, Lee M-S, et al. Serial determination of the bcl-2 gene in the bone marrow and peripheral blood after central lymphatic irradiation for stages I-III follicular lymphoma: a preliminary report. Clin Cancer Res 1997; 3: 215-219.
5. Petersen PM, Gospodarowicz M, Tsang R, et al. Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone. J Clin Oncol 2004; 22(14S): 563.
6. Mac Manus M, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14: 1282-1290.
7. Gospodarowicz M, Bush R, Brown T, et al. Curability of gastrointestinal lymphoma with combined surgery and radiation. Int J Radiat Oncol Biol Phys 1983; 9: 3-9.
8. Gospodarowicz MK, Bush RS, Brown TC, et al. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret experience. Int J Radiat Oncol Biol Phys 1984; 10: 489-497.
9. Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, et al. Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 1994; 69: 1088-1093.
10. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004; 22: 1454-1459.
11. Johannsson J, Specht L, Mejer J, et al. Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Int J Radiat Oncol Biol Phys 2002; 54: 1466-1470.
12. Haas RL, Girinsky T. HOVON 47/EORTC 20013: chlorambucil vs 2 × 2 Gy involved field radiotherapy in stage III/IV previously untreated follicular lymphoma patients. Ann Hematol 2003; 82: 458-462.
13. Haas RL, Poortmans P, de Jong D, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 2003; 21: 2474-2480.
14. Soubeyran P, Eghbali H, Bonichon F, et al. Localized follicular lymphomas: prognosis and survival of stages I and II in a retrospective series of 103 patients. Radiother Oncol 1988; 13: 91-98.
15. Monfardini S, Banfi A, Bonadonna G, et al. Improved 5 year survival after combined radiotherapy-chemotherapy for stage I and II non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 1980; 6: 125-134.
16. Nissen NI, Ersboll J, Hansen HS, et al. A randomized study of radiotherapy versus radiotherapy plus chemotherapy in Stage I-II Non-Hodgkin's lymphomas. Cancer 1983; 52: 1-7.
17. Kelsey SM, Newland AC, Hudson GV, et al. A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma. Med Oncol 1994; 11: 19-25.
18. Seymour JF, Pro B, Fuller LM, et al. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 2115-2122.
19. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-1423.
20. Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005; 23: 694-704.
21. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441-449.
22. Hagenbeek A, Lewington V. Report of a European consensus workshop to develop recommendations for the optimal use of 90Y-ibritumomab tiuxetan (Zevalin(R)) in lymphoma. Ann Oncol 2005; 16: 786-792.
23. Tsang RW, Gospodarowicz MK, O'Sullivan B. Staging and management of localized non-Hodgkin's lymphomas: variations among experts in radiation oncology. Int J Radiat Oncol Biol Phys 2002; 52: 643-651.
24. Stuschke M, Hoederath A, Sack H, et al. Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas: results of a prospective multicenter study. Study Group NHL-fruhe Stadien. Cancer 1997; 80: 2273-2284.
25. De Los Santos JF, Mendenhall NP, Lynch JW. Is comprehensive lymphatic irradiation for low-grade Non-Hodgkin's lymphoma curative therapy? Long-term experience at a single institution. Int J Radiat Oncol Biol Phys 1997; 38: 3-8.
26. Ha CS, Kong JS, Tucker SL, et al. Central lymphatic irradiation for stage I-III follicular lymphoma: report from a single-institutional prospective study. Int J Radiat Oncol Biol Phys 2003; 57: 316-320.
27. Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003; 101: 2489-2495.
28. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003; 21: 4157-4164.
29. Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed (published erratum appears in Blood 2000 Apr 15; 95(8):2481). Blood 2000; 95: 802-806.
30. Isaacson PG. Update on MALT lymphomas. Best Pract Res Clin Haematol 2005; 18: 57-68.
31. Ferreri AJ, Guidoboni M, Ponzoni M, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004; 96: 586-594.
32. Ferreri AJ, Ponzoni M, Guidoboni M, et al. Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol 2005; Epub ahead of print.
33. Cerroni L, Zochling N, Putz B, et al. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol 1997; 24: 457-461.
34. Wood GS, Kamath NV, Guitart J, et al. Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States. J Cutan Pathol 2001; 28: 502-507.
35. Munksgaard L, Frisch M, Melbye M, et al. Incidence patterns of Lyme's disease and cutaneous B-cell non-Hodgkin's lymphoma in the United States. Dermatology 2000; 201: 351-352.
36. Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 1995; 345: 1591-1594.
37. Fischbach W, Goebeler-Kolve ME, Dragosics B, et al. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 2004; 53: 34-37.
38. Savio A, Zamboni G, Capelli P, et al. Relapse of low-grade gastric MALT lymphoma after Helicobacter pylori eradication: true relapse or persistence? Long-term post-treatment follow-up of a multicenter trial in the north-east of Italy and evaluation of the diagnostic protocol's adequacy. Rec Results Cancer Res 2000; 156: 116-124.
39. Pinotti G, Zucca E, Roggero E, et al. Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. Leuk Lymph 1997; 26: 527-537.
40. Inagaki H, Nakamura T, Li C, et al. Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter pylori eradication and detection of API2-MALT1 fusion. Am J Surg Pathol 2004; 28: 1560-1567.
41. Zucca E, Bertoni F, Roggero E, et al. The gastric marginal zone B-cell lymphoma of MALT type. Blood 2000; 96: 410-419.
42. Veldhuyzen van Zanten SJ, Sherman PM, Hunt RH. Helicobacter pylori: new developments and treatments. Cmaj 1997; 156: 1565-1574.
43. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-180.
44. Marshall BJ, Windsor HM. The relation of Helicobacter pylori to gastric adenocarcinoma and lymphoma: pathophysiology, epidemiology, screening, clinical presentation, treatment, and prevention. Med Clin North Am 2005; 89: 313-344, viii.
45. Liu H, Ye H, Ruskone-Fourmestraux A, et al T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002; 122: 1286-1294.
46. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001; 357: 39-40.
47. Taji S, Nomura K, Matsumoto Y, et al. Trisomy 3 may predict a poor response of gastric MALT lymphoma to Helicobacter pylori eradication therapy. World J Gastroenterol 2005; 11: 89-93.
48. Ye H, Liu H, Raderer M, et al. High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood 2003; 101: 2547-2550.
49. Fischbach W, Goebeler-Kolve M, Starostik P, et al. Minimal residual low-grade gastric MALT-type lymphoma after eradication of Helicobacter pylori. Lancet 2002; 360: 547-548.
50. Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 1998; 16: 1916-1921.
51. Fung CY, Grossbard ML, Linggood RM, et al. Mucosa-associated lymphoid tissue lymphoma of the stomach: long term outcome after local treatment. Cancer 1999; 85: 9-17.
52. Bertoni F, Conconi A, Capella C, et al. Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. Blood 2002; 99: 2541-2544.
53. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005; 23: 1979-1983.
54. Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003; 102: 2741-2745.
55. Raderer M, Jager G, Brugger S, et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 2003; 65: 306-310.
56. Wohrer S, Drach J, Hejna M, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann Oncol 2003; 14: 1758-1761.
57. Hitchcock S, Ng AK, Fisher DC, et al. Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2002; 52: 1058-1066.
58. Le QT, Eulau SM, George TI, et al. Primary radiotherapy for localized orbital MALT lymphoma. Int J Radiat Oncol Biol Phys 2002; 52: 657-663.
59. Zinzani PL, Magagnoli M, Galieni P, et al. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol 1999; 17: 1254-1258.
60. Thieblemont C, Bastion Y, Berger F, et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol 1997; 15: 1624-1630.
61. Tsang RW, Gospodarowicz MK. Management of localized (stage I and II) clinically aggressive lymphomas. Ann Hematol 2001; 80(Suppl. 3): B66-B72.
62. Pelloski CE, Wilder RB, Ha CS, et al. Clinical stage IEA-IIEA orbital lymphomas: outcomes in the era of modern staging and treatment. Radiother Oncol 2001; 59: 145-151.
63. Uno T, Isobe K, Shikama N, et al. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multiinstitutional, retrospective review of 50 patients. Cancer 2003; 98: 865-871.
64. Fung CY, Tarbell NJ, Lucarelli MJ, et al. Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes. Int J Radiat Oncol Biol Phys 2003; 57: 1382-1391.
65. Agulnik M, Tsang R, Baker MA, et al. Malignant lymphoma of mucosa-associated lymphoid tissue of the lacrimal gland: case report and review of literature. Am J Clin Oncol 2001; 24: 67-70.
66. Pfeffer MR, Rabin T, Tsvang L, et al. Orbital lymphoma: is it necessary to treat the entire orbit? Int J Radiat Oncol Biol Phys 2004; 60: 527-530.
67. Dunbar SF, Linggood RM, Doppke KP, et al. Conjunctival lymphoma: results and treatment with a single anterior electron field. A lens sparing approach. Int J Radiat Oncol Biol Phys 1990; 19: 249-257.
68. Gordan KB, Char DH, Sagerman RH. Late effects of radiation on the eye and ocular adnexa. Int J Radiat Oncol Biol Phys 1995; 31: 1123-1139.
69. Bessell EM, Henk JM, Wright JE, et al. Orbital and conjunctival lymphoma treatment and prognosis. Radiother Oncol 1988; 13: 237-244.
70. Matsuo T, Yoshino T. Long-term follow-up results of observation or radiation for conjunctival malignant lymphoma. Ophthalmology 2004;111:1233-1237.
71. Balm AJ, Delaere P, Hilgers FJ, et al. Primary lymphoma of mucosa associated lymphoid tissue (MALT) in the parotid gland. Clin Otolaryngol 1993; 18: 528-532.
72. Cerroni L, Signoretti S, Hofler G, et al. Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. Am J Surg Pathol 1997; 21: 1307-1315.
73. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
74. Roggero E, Zucca E, Mainetti C, et al. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum Pathol 2000; 31: 263-268.
75. Kurtin PJ, DiCaudo DJ, Habermann TM, et al. Primary cutaneous large cell lymphomas. Morphologic, immunophenotypic, and clinical features of 20 cases. Am J Surg Pathol 1994; 18: 1183-1191.
76. Rijlaarsdam JU, Toonstra J, Meijer O, et al. Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: a clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy. J Clin Oncol 1996; 14: 549-555.
77. King LJ, Padley SP, Wotherspoon AC, et al. Pulmonary MALT lymphoma: imaging findings in 24 cases. Eur Radiol 2000; 10: 1932-1938.
78. Zinzani PL, Tani M, Gabriele A, et al. Extranodal marginal zone B-cell lymphoma of MALT-type of the lung: single-center experience with 12 patients. Leuk Lymph 2003; 44: 821-824.
79. Thieblemont C, Mayer A, Dumontet C, et al. Primary thyroid lymphoma is a heterogeneous disease. J Clin Endocrinol Metab 2002; 87: 105-111.